Sensei Biotherapeutics, Inc. Common Stock
SNSESensei Biotherapeutics, Inc. (SNSE) is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies. The company specializes in designing vaccine and antibody-based treatments to target underlying mechanisms of cancer and improve immune response. Its proprietary platform aims to address unmet needs in cancer care through personalized and novel immunotherapies.
Company News
Sensei Biotherapeutics announced promising Phase 1/2 trial results for solnerstotug, a monoclonal antibody targeting VISTA, showing 50% 6-month progression-free survival in PD-(L)1 resistant tumors at the 15 mg/kg dose, with plans to advance to Phase 2 studies in Non-Small Cell Lung Cancer and Merkel Cell Carcinoma.
VISTA inhibitors are an emerging class of immunotherapeutic agents with significant potential in treating cancer and autoimmune diseases. Several companies are actively pursuing VISTA inhibitors, which offer a novel mechanism of action and broad applicability, but also face challenges such as complex development landscape and competition from exi...
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conf...
- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity -
- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities -
